CA1275928C - Suppression of withdrawal symptoms in opioid-induced tolerance or dependence - Google Patents
Suppression of withdrawal symptoms in opioid-induced tolerance or dependenceInfo
- Publication number
- CA1275928C CA1275928C CA000508574A CA508574A CA1275928C CA 1275928 C CA1275928 C CA 1275928C CA 000508574 A CA000508574 A CA 000508574A CA 508574 A CA508574 A CA 508574A CA 1275928 C CA1275928 C CA 1275928C
- Authority
- CA
- Canada
- Prior art keywords
- calcium channel
- channel blocking
- pharmaceutical composition
- blocking drug
- opioid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73366485A | 1985-05-13 | 1985-05-13 | |
US733,664 | 1985-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1275928C true CA1275928C (en) | 1990-11-06 |
Family
ID=24948609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000508574A Expired - Lifetime CA1275928C (en) | 1985-05-13 | 1986-05-07 | Suppression of withdrawal symptoms in opioid-induced tolerance or dependence |
Country Status (6)
Country | Link |
---|---|
US (1) | US4797410A (de) |
EP (1) | EP0204951B1 (de) |
JP (1) | JPS61260025A (de) |
AT (1) | ATE84713T1 (de) |
CA (1) | CA1275928C (de) |
DE (1) | DE3687541T2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3806277A1 (de) * | 1988-02-27 | 1989-09-07 | Troponwerke Gmbh & Co Kg | Verwendung von 1,4-dihydropyridin-derivaten |
WO1990011074A1 (en) * | 1989-03-22 | 1990-10-04 | Pang Peter K T | Parathyroid hypertensive factor |
US5886012A (en) * | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
CA2016465A1 (en) * | 1989-06-02 | 1990-12-02 | Zola Phillip Horovitz | Method for preventing or treating anxiety employing a calcium channel blocker |
US5124340A (en) * | 1989-06-28 | 1992-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of calcium channel blocker to prevent ***e induced craving and reinforcement |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
IL109460A (en) | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
DE69722191T2 (de) * | 1996-03-08 | 2004-04-01 | Nycomed Danmark Aps | Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
BRPI0015284B8 (pt) | 1999-10-29 | 2021-05-25 | Euro Celtique S/A | formulações de hidrocodona de liberação controlada |
GB0019055D0 (en) * | 2000-08-03 | 2000-09-27 | Unilever Plc | Antiperspirant and deodorant products and methods for their use |
KR101045144B1 (ko) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
CA2671197A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
US20170071879A1 (en) * | 2015-09-15 | 2017-03-16 | Alexandre Vamvakides | Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline) |
GR1009145B (el) * | 2016-08-10 | 2017-10-20 | Αλεξανδρος Δημητριου Βαμβακιδης | Πρωτοτυπη αναλγητικη δραση της 3,3-διφαινυλο-ν-(1-φαινυλαιθυλ) προπαν-1-αμινη (fendiline) |
-
1986
- 1986-05-05 DE DE8686106111T patent/DE3687541T2/de not_active Expired - Fee Related
- 1986-05-05 AT AT86106111T patent/ATE84713T1/de not_active IP Right Cessation
- 1986-05-05 EP EP86106111A patent/EP0204951B1/de not_active Expired - Lifetime
- 1986-05-07 CA CA000508574A patent/CA1275928C/en not_active Expired - Lifetime
- 1986-05-12 JP JP61106882A patent/JPS61260025A/ja active Granted
-
1987
- 1987-04-16 US US07/040,755 patent/US4797410A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0204951A2 (de) | 1986-12-17 |
JPH0584287B2 (de) | 1993-12-01 |
EP0204951A3 (en) | 1990-05-30 |
JPS61260025A (ja) | 1986-11-18 |
DE3687541T2 (de) | 1993-05-13 |
DE3687541D1 (de) | 1993-03-04 |
ATE84713T1 (de) | 1993-02-15 |
US4797410A (en) | 1989-01-10 |
EP0204951B1 (de) | 1993-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1275928C (en) | Suppression of withdrawal symptoms in opioid-induced tolerance or dependence | |
US3966940A (en) | Analgetic compositions | |
Martin | History and development of mixed opioid agonists, partial agonists and antagonists. | |
US4315936A (en) | Analgesic composition | |
US20060167032A1 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
EP0270290A3 (de) | Methode und Präparate zur Reduzierung neurotoxischer Schäden | |
AU2003210486A1 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
EP0932416A2 (de) | Verfahren und potenzierte zusammensetzung zur behandlung von migräne | |
WO2004000354A2 (en) | Method of treating the syndrome of lipodystrophy | |
WO2001052851A1 (en) | Methods for the treatment of substance abuse | |
JP2003520234A (ja) | 薬物中毒の治療方法 | |
EP0514023B1 (de) | Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen | |
WO1992014464A1 (en) | Use of sigma receptor antagonists for treatment of ***e abuse | |
EP0844241B1 (de) | Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika | |
Ronai et al. | Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series. | |
CA1322523C (en) | Central nervous system injury treatment with opiate- receptor antagonists | |
US5025018A (en) | Central nervous system injury treatment with opiate-receptor antagonist | |
EP0013110B1 (de) | Analgetikum | |
NZ206121A (en) | Analgesic compositions containing alpha-methyl-4-(2-thienylcarbonyl)-benzene-acetic acid | |
Maxwell et al. | Naloxone | |
Sophronov et al. | Nifedipine but not verapamil inhibits subjective effects of iv morphine in opiate‐dependent patients | |
McMillan et al. | Effects of N‐substituted analogs of (−)‐α‐acetylmethadol and (−)‐α‐methadol on schedule‐controlled behavior | |
Cowan et al. | An In Vivo Pharmacological Analysis of Benzomorphan Binding Sites in Rats | |
AU2001226574A1 (en) | Methods for the treatment of substance abuse | |
EP0480458A2 (de) | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend Viminol zur Behandlung von Drogenabhängigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry | ||
MKEX | Expiry |
Effective date: 20071106 |